triheptanoin   Click here for help

GtoPdb Ligand ID: 11431

Synonyms: Dojolvi® | UX-007 | UX007
Approved drug
triheptanoin is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Triheptanoin is a medium-chain triglyceride that is administered as a rescue therapeutic in patients with long-chain fatty acid oxidation disorders [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 23
Topological polar surface area 78.9
Molecular weight 428.31
XLogP 7.93
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCCCC(=O)OC(COC(=O)CCCCCC)COC(=O)CCCCCC
Isomeric SMILES CCCCCCC(=O)OC(COC(=O)CCCCCC)COC(=O)CCCCCC
InChI InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3
InChI Key PJHKBYALYHRYSK-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The FDA approved triheptanoin in June 2020, as a treatment for patients with long-chain fatty acid oxidation disorders. It provides a source of calories and fatty acids. Triheptanoin is not yet apporved by the EMA, but has been granted orphan designation for use to treat several glycogen storage and long-chain fatty acid oxidation disorders.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01886378 A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Phase 2 Interventional Ultragenyx Pharmaceutical Inc 2-3
External links Click here for help
For extended ADME data see the following:

Drugs.com